DATE – Talk Bio

FDA Approves Updated COVID-19 Shots from Pfizer, Moderna, Novavax with New Restrictions

4 days ago talkbio0Tagged COVID19 (disease), high-risk groups, LP.8.1 sublineage, Moderna, Novavax, Pfizer, restrictions, United States Food and Drug Administration, Vaccines

FDA; COVID-19 vaccine; Pfizer; Moderna; Novavax; vaccine restrictions; high-risk groups; 2025-2026 booster; LP.8.1 sublineage

Fierce Biotech Layoff Tracker 2025: Abata Folds; Generation Lays Off 90% of Staff

3 weeks ago talkbio0Tagged Abata, Biotech Layoff Tracker, Biotech Layoffs, company closure, Fierce, Generations, Staff

biotech layoffs; Abata; Generation; Fierce Biotech Layoff Tracker; 2025; company closure; staff reduction

Uncertainty Clouds Finances for Payers and Health Systems in Q2 2025

3 weeks ago talkbio0Tagged Budgets, Changing, Consumer, federal, health systems, healthcare financial performance, Hospital admission, Medicaid, Medicare, payers, Policy, Q2 2025, Uncertainty

Q2 2025; healthcare financial performance; payers; health systems; uncertainty; Medicaid; Medicare; admissions; policy changes; federal budget; consumer confidence

Assembly Bio Reports Phase 1b Success in Herpes; Gilead Increases Stake with 2.3M Shares

3 weeks ago talkbio0Tagged ABI-5366, Assembly (construction), Bio, Collaboration, genital lesion reduction, Gilead Sciences, herpesvirus 2, human, safety profile, Simplexvirus, stock purchase, viral shedding

Assembly Bio; Phase 1b trial; ABI-5366; herpes simplex virus (HSV-2); viral shedding reduction; genital lesion reduction; safety profile; Gilead Sciences; collaboration; stock purchase

Lilly’s Q2 2025 Beat-and-Raise Overshadowed by Orforglipron Data

4 weeks ago talkbio0Tagged earnings, Eli, Eli Lilly, Expectations, franchise, Glucagon-Like Peptide 1, Obesity, Oral cavity, orforglipron, Q2 2025, regulatory submission, Weight Loss

Eli Lilly; Q2 2025 earnings; orforglipron; oral GLP-1; weight loss; obesity franchise; regulatory submission; analyst expectations

Sarepta Pursues Efficiency Measures Amid $1 Billion Debt Due in 2027

4 weeks ago talkbio0Tagged 2025, debt, decline, Efficiency, ELEVIDYS, Financial cost, financial results, Financial savings, Measures, Muscular Dystrophy, Duchenne, restructuring, United States Food and Drug Administration

Sarepta Therapeutics; debt 2027; efficiency measures; ELEVIDYS; cost savings; restructuring; financial results 2025; FDA; Duchenne muscular dystrophy; stock decline